Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Would you offer adjuvant radiation therapy for a completely resected, node positive mucoepidermoid carcinoma of the lung?
Related Questions
How do you assess whether a patient will be a good DIBH candidate for lung or abdomen treatments?
Given the findings of SUNSET, demonstrating 60 Gy in 8 fractions to be a safe and effective regimen for ultracentral lesions, in what situations would you elect to use a 10 fraction hypofractionated regimen?
What is your approach to radiographically suspicious lung nodules for which initial biopsy was negative for malignancy?
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?
Would you consider omission of PORT for node+ NSCLC with a positive margin in the setting of a high tumor PD-L1 score and plans for immunotherapy?
Do you still offer adjuvant chemotherapy and chemoradiation for NSCLC after neoadjuvant chemoimmunotherapy?
Would a metal endobronchial stent within the treatment field change your radiation treatment plan for a thoracic malignancy?
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
What dose contraints do use for the pulmonary artery and vein when treating with a lung lesion with SBRT?
Do you restrict the dose rate during treatment delivery to a pacemaker in addition to limiting the Dmax?
